NasdaqCM - Delayed Quote USD

Evoke Pharma, Inc. (EVOK)

Compare
5.40 -0.14 (-2.53%)
At close: 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Matthew J. D'Onofrio MBA Co-Founder, CEO & Director 779.37k -- 1970
Dr. Marilyn R. Carlson D.M.D., M.D., RAC. Chief Medical Officer 681.24k -- 1948
Mr. Mark A. Kowieski CPA Chief Financial Officer -- -- 1977
Mr. Christopher Quesenberry Chief Commercial Officer - Gimoti (TM) -- -- --

Evoke Pharma, Inc.

420 Stevens Avenue
Suite 230
Solana Beach, CA 92075
United States
858 345 1494 https://www.evokepharma.com
Sector:?
Healthcare
Full Time Employees:?
4

Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Corporate Governance

Evoke Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 1:30 PM UTC - November 11, 2024 at 1:30 PM UTC

Evoke Pharma, Inc. Earnings Date

Recent Events

October 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 9, 2024 at 11:00 AM UTC

at HC Wainwright Global Investment Conference

September 4, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

August 29, 2024 at 12:00 AM UTC

S-3: Offering Registrations

August 19, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

August 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 15, 2024 at 8:00 AM UTC

Q2 2024 Earnings Call

August 13, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers